ARTICLES BY LOUIS GARGUILO

  • iStock-1179976609
    Are You Outsourcing Your Future?
    8/20/2021

    Today drug development and manufacturing outsourcing is a ubiquitous business-enabling activity to gain entrée to advanced technologies and capabilities. Those are the capabilities upon which your programs and overall organization are centered. Are you, then, outsourcing your future?

  • Top 5
    Five Maxims For Outsourcing Success
    6/8/2021

    "Outsourcing is really about positioning your CDMO to your competitive advantage," says Lis Wyman of Acceleron Pharma. That might just be the "maximum maxim" for outsourcing strategy. But Wyman has four more to offer, all enlightening to your craft of drug development and manufacturing.

  • Louis
    Patheon Surfs Outsourcing Waves And Scoops Up Gallus Along The Way
    8/28/2014

    Jim Mullen, CEO of Patheon parent company DPx Holdings B.V., is at it again.

    On the heels of my three-part series with Mullen on the details behind the springtime merger of his company and the pharmaceutical products division of Royal DSM, he has made his next move.

    This time it is a strategic entrée into the U.S.-based market for biologics services via an acquisition of privately held Gallus BioPharmaceuticals. With Gallus, Patheon adds new capabilities at well-established sites with name-brand clientele, in St. Louis, Mo. and Princeton, N.J., to its global locations in Groningen, the Netherlands and Brisbane, Australia.

  • Garguilo_Photo_2015
    Pharmaceutical Customers In An Outsourcing Provider Merger -- Part 3 Of Interview With CEO of Newly Formed DPx Holdings B.V.
    7/1/2014

    This final article in our series featuring Jim Mullen, CEO of newly formed DPx Holdings B. V., discusses how to keep the focus on customers during M&A activity, and the broader transformation of sponsor–provider relationships in the pharmaceutical outsourcing industry.

  • Garguilo
    Quality, Capacity And Job Security In A CMO Industry Merger -- Part 2 Of Our Interview With CEO Of Newly Formed DPx Holdings B.V.

    This spring Jim Mullen became CEO of DPx Holdings B.V., formed in a $2.65 billion transaction combining JLL Partners’ assets Patheon and Banner Life Sciences, with Royal DSM’s Pharmaceuticals business. In an interview with Outsourced Pharma, Mullen discusses three key components in a merger: quality, capacity and job security.

    With a merger nearing completion and the integration plans underway, Mullen says you have to start with the fundamental ABCs of business. “There are three fundamental questions to get to day one: Do you have the right financial controls? Can you reliably continue to pay your suppliers? Can you receive cash and can you make payroll?

louis-g-photo-edited

Louis Garguilo



Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.

Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.